CultureMore in Culture→
Novo Nordisk and Hims Strike Deal That Could End Compounded GLP-1s
Key Takeaways
- Novo Nordisk and Hims settle legal dispute with commercial partnership
- Hims will shift from compounded semaglutide to branded Novo products
- Deal could reduce access to affordable compounded GLP-1 alternatives
- Global GLP-1 market projected to exceed $100 billion by 2030
DE
DT Editorial Team··4 min read·via gizmodo.com